Cyclic regimens using cyclocarbamate and cyclic amide derivatives
    21.
    发明授权
    Cyclic regimens using cyclocarbamate and cyclic amide derivatives 失效
    使用环状氨基甲酸酯和环状酰胺衍生物的循环方案

    公开(公告)号:US06380178B1

    公开(公告)日:2002-04-30

    申请号:US09552545

    申请日:2000-04-19

    IPC分类号: A61K3156

    摘要: This invention relates to cyclic combination therapies and regimens utilizing, in combination with progestins, substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: where A and B are independent substituents selected from S, CH or N; provided that when A is S, B is CH or N; and when B is S, A is CH or N; and A and B cannot both be CH; and when A and B both equal N, one N may be optionally substituted with an C1 to C6 alkyl group; R1 and R2 are independent substituents selected from the group of H, C1 to C6 alkyl, substituted C1 to C6 alkyl, C2 to C6 alkenyl, substituted C2 to C6 alkenyl, C2 to C6 alkynyl, substituted C2 to C6 alkynyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, CORA, or NRBCORA; or R1 and R2 are fused to form optionally substituted 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic ring, the heterocyclic ring containing one to three heteroatoms selected from the group of O, S and N; or pharmaceutically useful salts thereof. These methods of treatment may be used for contraception.

    摘要翻译: 本发明涉及利用与孕激素组合的取代二氢吲哚衍生物化合物的循环组合疗法和方案,所述二氢吲哚衍生化合物是具有以下通式结构的孕酮受体的拮抗剂:其中A和B是选自S,CH或N的独立取代基; 条件是当A为S时,B为CH或N; 当B为S时,A为CH或N; A和B不能同时为CH; 并且当A和B均等于N时,一个N可以任选地被C 1至C 6烷基取代; R1和R2是选自H,C1至C6烷基,取代C1至C6烷基,C2至C6烯基,取代C2至C6烯基,C2至C6炔基,取代C2至C6炔基,C3至C8环烷基的独立取代基 取代的C 3至C 8环烷基,芳基,取代的芳基,杂环,取代的杂环,CORA或NRBCORA; 或R 1和R 2稠合形成任选取代的3至8元螺环烷基,烯基或杂环,所述杂环含有一至三个选自O,S和N的杂原子; 或其药学上有用的盐。 这些治疗方法可用于避孕。

    Combination regimens using progesterone receptor modulators
    27.
    发明授权
    Combination regimens using progesterone receptor modulators 失效
    使用孕酮受体调节剂的联合治疗方案

    公开(公告)号:US06759408B2

    公开(公告)日:2004-07-06

    申请号:US10141792

    申请日:2002-05-09

    IPC分类号: A61K31535

    摘要: This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1 and R2 may be single substituents or fused; R3 is H, OH, NH2, C1 to C6 alkyl, CORC, or optionally substituted C1 to C6 alkyl, C3 to C6 alkenyl, or alkynyl; RC is H, or optionally substituted C1 to C3 alkyl, aryl, C1 to C3 alkoxy, or C1 to C3 aminoalkyl; R4 is H, halogen, CN, NO2, or optionally substituted C1 to C6 alkyl, alkynyl, C1 to C6 alkoxy, amino, or C1 to C6 aminoalkyl; and R5 is a benzene ring, a five or six membered heterocyclic ring; or pharmaceutically acceptable salt thereof. Methods of treatment include contraception, secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, carcinomas, adenocarcinomas minimization of side effects, or food intake stimulation.

    摘要翻译: 本发明涉及使用具有通式结构的孕酮受体的拮抗剂的取代的二氢吲哚衍生物化合物的环状组合疗法和方案:其中R 1和R 2可以是单个取代基或稠合的; R 3是H,OH,NH 2,C 1 -C 6烷基,COR C或任选取代的C 1 -C 6烷基,C 3至C 6烯基或炔基; R C是H或任选取代的C 1至C 3烷基,芳基,C 1至C 3烷氧基或C 1至C 3氨基烷基; R 4是H,卤素,CN,NO 2或任选取代的C 1至C 6烷基,炔基,C 1至C 6烷氧基,氨基或C 1至C 6氨基烷基; 和R 5为苯环,五或六元杂环; 或其药学上可接受的盐。 治疗方法包括避孕,继发性闭经,功能障碍性出血,子宫平滑肌瘤,子宫内膜异位症,多囊卵巢综合征,癌,腺癌最小化副作用或食物摄取刺激。

    Cyclic urea and cyclic amide derivatives
    29.
    发明授权
    Cyclic urea and cyclic amide derivatives 失效
    环状脲和环状酰胺衍生物

    公开(公告)号:US06369056B1

    公开(公告)日:2002-04-09

    申请号:US09552356

    申请日:2000-04-19

    IPC分类号: A61K31535

    CPC分类号: C07D498/04

    摘要: This invention provides compounds of the formula: wherein: A, B and D are N or CH, with the proviso that A, B and D can not all be CH; R1 and R2 are independent substituents selected from H, CORA, NRBCORA, or optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or groups; or R1 and R2 are fused to form an optionally substituted 3 to 8 membered spirocyclic or heterocyclic ring; RA is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; RB is H, C1 to C3 alkyl, or substituted C1 to C3 alkyl; R3 is H, OH, NH2, or optionally substituted alkyl, or alkenyl, or CORC; RC is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; R4 is a substituted benzene ring or a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR5; RF is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; RG is H, alkyl, or substituted alkyl; R5 is H or alkyl; Q is O, S, NR6, or CR7R8; R6 is CN, SO2CF3, or optionally substituted alkyl, cycloalkyl, aryl, or heterocyclic ring; R7 and R8 are H, NO2, CN CO2R9, or optionally substituted alkyl, cycloalkyl, aryl, or heterocyclic; R9 is C1 to C3 alkyl; or CR7R8 form a six membered ring of the structure below: W is O or a chemical bond; or a pharmaceutically acceptable salt thereof, as well as their use and pharmaceutical compositions as agonists and antagonists of the progesterone receptor.

    摘要翻译: 本发明提供下式的化合物:其中:A,B和D为N或CH,条件是A,B和D不能全部为CH; R1和R2是选自H,CORA,NRBCORA或任选取代的烷基,烯基,炔基,环烷基,芳基或基团的独立取代基; 或R 1和R 2稠合形成任选取代的3至8元螺环或杂环; RA为H或任选取代的烷基,芳基,烷氧基或氨基烷基; RB是H,C 1至C 3烷基或取代的C 1至C 3烷基; R3是H,OH,NH2或任选取代的烷基或烯基或CORC; RC为H或任选取代的烷基,芳基,烷氧基或氨基烷基; R4是取代的苯环或具有1,2或3个杂原子的五或六元环,所述杂原子包括O,S,SO,SO 2或NR 5; RF是H或任选取代的烷基,芳基,烷氧基或氨基烷基; RG是H,烷基或取代的烷基; R5是H或烷基; Q是O,S,NR6或CR7R8; R6是CN,SO2CF3或任选取代的烷基,环烷基,芳基或杂环; R 7和R 8是H,NO 2,CN CO 2 R 9或任选取代的烷基,环烷基,芳基或杂环; R9为C1至C3烷基; 或CR7R8形成以下结构的六元环:W为O或化学键; 或其药学上可接受的盐,以及它们的用途和药物组合物作为孕激素受体的激动剂和拮抗剂。

    Cyclocarbamate and cyclic amide derivatives
    30.
    发明授权
    Cyclocarbamate and cyclic amide derivatives 失效
    环氨基甲酸酯和环酰胺衍生物

    公开(公告)号:US06306851B1

    公开(公告)日:2001-10-23

    申请号:US09552036

    申请日:2000-04-19

    IPC分类号: C07D49804

    CPC分类号: C07D498/04 A61K31/5365

    摘要: This invention provides compounds of the formula: wherein A and B are independent substituents selected from S, CH or N; provided that when A is S, B is CH or N; and when B is S, A is CH or N; and A and B cannot both be CH; and when A and B both equal N, one N may be optionally substituted with an C1 to C6 alkyl group; R1 and R2 are independent substituents selected from the group of H, C1 to C6 alkyl, substituted C1 to C6 alkyl, C2 to C6 alkenyl, substituted C2 to C6 alkenyl, C2 to C6 alkynyl, substituted C2 to C6 alkynyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, CORA, or NRBCORA; or R1 and R2 are fused to form optionally substituted 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic ring, the heterocyclic ring containing one to three heteroatoms selected from the group of O, S and N; or pharmaceutically useful salts thereof. The compounds of this invention are useful as agonists and antagonists of the progesterone receptor and in methods of inducing contraception and in the treatment or prevention of benign or malignant neoplastic diseases.

    摘要翻译: 本发明提供下式的化合物:其中A和B是选自S,CH或N的独立取代基; 条件是当A为S时,B为CH或N; 当B为S时,A为CH或N; A和B不能同时为CH; 并且当A和B均等于N时,一个N可以任选地被C 1至C 6烷基取代; R1和R2是选自H,C1至C6烷基,取代C1至C6烷基,C2至C6烯基,取代C2至C6烯基,C2至C6炔基,取代C2至C6炔基,C3至C8环烷基的独立取代基 取代的C 3至C 8环烷基,芳基,取代的芳基,杂环,取代的杂环,CORA或NRBCORA; 或R 1和R 2稠合形成任选取代的3至8元螺环烷基,烯基或杂环,所述杂环含有一至三个选自O,S和N的杂原子; 或其药学上有用的盐。 本发明的化合物可用作孕激素受体的激动剂和拮抗剂以及诱导避孕和治疗或预防良性或恶性肿瘤疾病的方法。